Apr 21, 2023 7:00am EDT XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Polycystic Kidney Disease
Feb 01, 2023 7:00am EST XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease
Jan 03, 2023 7:00am EST XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression
Dec 08, 2022 7:00am EST XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Nov 28, 2022 7:00am EST XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
Nov 25, 2022 5:45pm EST XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency